4 results for "Hjortland".
Introduction: Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) G3 are rare with a poor outcome. Molecular data for GEP NEN G3 is limited and the 2019 WHO classification is based on morphology and proliferation rate.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: MSc Andreas Venizelos
Introduction: Gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs) are aggressive, highly proliferating tumors. Therapeutic response to current chemotherapy regimens is usually short-lasting.
Conference: 13th Annual ENETS conference 2016 (2016)
Presenting Author: PhD student Abeir Ali
Introduction: Gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) are generally characterized by synchronous metastases, high aggressiveness and a dismal prognosis. Currently, resection of liver metastases in patients with metastatic GEP-NEC is not recommended. However, the existing data are scarce.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Surgical treatment
Presenting Author: MD Renate Berget Galleberg
Introduction: High-grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs, G3) are aggressive cancers of the digestive system with poor prognosis and survival. Platinum-based chemotherapy (cisplatin/carboplatin +etoposide) is considered standard first-line palliative treatment. Etoposide is frequently administered intravenously, however oral etoposide is often used as an alternative. Concerns for oral etoposide include decreased bioavailability, inter- & intrapatient variability and patient compliance.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: PhD Student Abir A Ali